Tempus AI Expands Lung Cancer Screening Through Median Technologies Partnership
Tempus AI partners with Median Technologies to integrate FDA-cleared eyonis LCS lung cancer screening software into its Pixel platform, marking the first US distribution agreement for the diagnostic tool.
Median Technologies has forged a partnership with Tempus AI, setting the former company up with its first US distribution agreement for eyonis lung cancer screening (LCS) since the software's US Food and Drug Administration (FDA) clearance on 9 February. Under the partnership, eyonis LCS will be integrated into Tempus Pixel, Tempus AI's artificial intelligence (AI) cardiac imaging platform.
Tempus Pixel's tools include advanced analytics and automated reporting from radiology images to assist healthcare providers in tracking and quantifying lesions across a range of cancer types. Integrating eyonis LCS into its ecosystem will allow clinical teams to stratify and prioritise patients in lung cancer screening programmes by characterising CT-identified lung nodules with Median's proprietary nodule malignancy score tool.
Median's FDA clearance for eyonis LCS, a Software as a Medical Device (SaMD) designed to analyse imaging data generated from CT scans to assist radiologists in evaluating pulmonary nodules on lungs, was based on data from the company's RELIVE (NCT06751576) pivotal trial. Meeting its primary endpoint, RELIVE demonstrated that in its use alongside a radiologist, eyonis registered a statistically significant improvement of p=0.027 over a radiologist alone.
In 2026, the American Cancer Society (ACS) estimates that there will be around 229,410 new lung cancer cases and 124,990 deaths in the US. According to 2024 research by the ACS, only one in five eligible adults in the US were screened for lung cancer in 2024, while ACS predicts that over 62,000 lives could be saved over five years if 100% of those eligible were screened.
A senior vice president and general manager of AI products at Tempus AI said the collaboration would improve the standard of care and help prevent avoidable deaths through better screening access. The founder and CEO of Median Technologies stated that activating the distribution collaboration with Tempus AI is a decisive step in bringing eyonis LCS to patients at national scale, noting that Tempus' strong leadership in AI-enabled precision medicine, deeply integrated data-technology ecosystem, and strong market presence make them an exceptional partner to drive rapid and high-impact adoption of eyonis LCS across the US.
Tempus AI generated revenue of $1.59 billion in 2025 and expects to achieve 25% growth year-over-year in 2026. The Chicago-based company has continued to advance its diagnostic value proposition via acquisitions and partnerships that supplement the diagnostic testing services that represent the bulk of its revenue stream.
In February 2025, Tempus partnered with Artera to expand access to the latter's AI-based prostate cancer test, and acquired AI digital pathology company Paige in August 2025 to expand its digital pathology datasets. The launch of Paige Predict in January 2026 extends Tempus's AI-driven diagnostics into digital pathology across 16 cancer types.
Social media chatter highlights Tempus AI's expansive multimodal dataset powering diagnostics and treatments in oncology and cardiology. Investors applaud high-margin data services growth nearing 30% organically, alongside strategic acquisitions like Ambry Genetics adding revenue streams. Discussions note the stock trading at around 7.6 times annualized revenues, below recent averages, prompting some to accumulate shares. Robust cash reserves offer multi-year runway despite operating burn. Traders eye upcoming March earnings for confirmation of growth trajectory and AI monetization.